Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect

CORC > 厦门大学 > 材料学院－已发表论文

	Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect
	Jia, Mengmeng ; Li, Yang ; Yang, Xiangrui ; Huang, Yuancan ; Wu, Hongjie ; Hueng, Yu ; Lin, Jinya ; Li, Yanxiu ; Hou, Zhenqing ; Zhang, Qiqing ; Hou ZQ(侯振清) ; Zhang QQ(张其清)
刊名	http://dx.doi.org/10.1021/am501932s
	2014
关键词	Chemotherapy Chitosan Diseases Drug delivery Drug products Molecular biology Nanoparticles Particle size analysis Tumors
英文摘要	Codelivery of multiple drugs with one kind of drug carriers provided a promising strategy to suppress the drug resistance and achieve the synergistic therapeutic effect in cancer treatment. In this paper, we successfully developed both methotrexate (MTX) and mitomycin C (MMC) loaded PEGylated chitosan nanoparticles (CS-NPs) as drug delivery systems, in which MTX, as a folic acid analogue, was also employed as a tumor-targeting ligand. The new drug delivery systems can coordinate the early phase targeting effect with the late-phase anticancer effect. The (MTX+MMC)-PEG-CS-NPs possessed nanoscaled particle size, narrow particle size distribution, and appropriate multiple drug loading content and simultaneously sustained drug release. In vitro cell viability tests indicated that the (MTX+MMC)-PEG-CS-NPs exhibited concentration- and time-dependent cytotoxicity. Moreover, in vitro cellular uptake suggested that the (MTX+MMC)-PEG-CS-NPs could be efficiently taken up by cancer cells by FA receptor-mediated endocytosis. On the other hand, the (MTX+MMC)-PEG-CS-NPs can codelivery MTX and MMC to not only achieve the high accumulation at the tumor site but also more efficiently suppress the tumor cells growth than the delivery of either drug alone, indicating a synergistic effect. In fact, the codelivery of two anticancer drugs with distinct functions and different anticancer mechanisms was key to opening the door to their targeted drug delivery and synergistic anticancer effect. Therefore, the (MTX+MMC)-PEG-CS-NPs as targeted drug codelivery systems might have important potential in clinical implications for combination cancer chemotherapy. ? 2014 American Chemical Society.
语种	英语
出版者	American Chemical Society
内容类型	期刊论文
源URL	[http://dspace.xmu.edu.cn/handle/2288/87427]
专题	材料学院－已发表论文
推荐引用方式 GB/T 7714	Jia, Mengmeng,Li, Yang,Yang, Xiangrui,et al. Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect[J]. http://dx.doi.org/10.1021/am501932s,2014.
APA	Jia, Mengmeng.,Li, Yang.,Yang, Xiangrui.,Huang, Yuancan.,Wu, Hongjie.,...&张其清.(2014).Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect.http://dx.doi.org/10.1021/am501932s.
MLA	Jia, Mengmeng,et al."Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect".http://dx.doi.org/10.1021/am501932s (2014).